Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims (canceled): 1 through 49.

Claim 50 (currently amended): A solid, oral, controlled release dosage form consisting of a therapeutically effective amount of oxycodone or oxycodone hydrochloride between about 30 and 65% by weight of a matrix-forming polymer selected from the group consisting of hydroxypropyl cellulose, hydroxypropylmethyl cellulose and hydroxyethyl cellulose and between about 1 and 20% by weight of a cationic exchange resin having a mean particle size of less than about 50 μm and a particle size distribution such that not less than 90% of the particles pass through a 325 mesh sieve, U.S. Standard Sieve Size, wherein the oxycodone or ~~oxycodine~~ oxycodone hydrochloride, the polymer and the cationic exchange resin are admixed with one another in dry form and then compressed.

Claim 51 (original): The dosage form of claim 50 wherein the cationic exchange resin comprises a sulfonated polymer.

Claim 52 (original): The dosage form of claim 50 wherein the cationic exchange resin comprises a copolymer of divinyl-benzene and styrene.

Claim 53 (original): The dosage form of claim 50 wherein the cationic exchange resin comprises a copolymer of divinylbenzene and methacrylic acid.

Claim 54 (original): The dosage form of claim 50 wherein the cationic exchange resin comprises phenolic-based polyamine condensates.